|
www.PicksThatMove.com: "Picks that move" Alerts, July 31, 2009: PSYS, AUXL, IDRA, SCMP, GTCB and MEDX.
(M2 PressWIRE Via Acquire Media NewsEdge) Picksthatmove.com Alerts include Psychiatric Solutions, Inc. (NASDAQ: PSYS); Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL); Idera Pharmaceuticals, Inc. (Nasdaq: IDRA); Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP); GTC Biotherapeutics, Inc.'s ("GTC", Nasdaq: GTCB) and Medarex, Inc. (NASDAQ: MEDX)
-- July 30, 2009 Psychiatric Solutions, Inc. (NASDAQ: PSYS) closed at $26.61 on a volume of 1,088,334 shares.
In a press release out on July 31, 2009 Psychiatric Solutions Agrees to Sell EAP Business to Aetna
FRANKLIN, Tenn., Jul 31, 2009 -- Psychiatric Solutions, Inc. ("PSI") (NASDAQ: PSYS) today announced that it has signed a definitive agreement to sell its employee assistance program ("EAP") business to Aetna for approximately $70 million in cash. PSI expects to complete the transaction in the fourth quarter of 2009. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino anti-trust approval and applicable regulatory approvals in California. For the first six months of 2009 PSI's EAP business produced revenue of approximately $22.6 million. PSI intends to use the net proceeds from the sale to reduce its debt.
PSI offers an extensive continuum of behavioral health programs to critically ill children, adolescents and adults and is the largest operator of owned or leased freestanding psychiatric inpatient facilities with over 10,000 beds in 31 states, Puerto Rico and the U.S. Virgin Islands. PSI also manages freestanding psychiatric inpatient facilities for government agencies and psychiatric inpatient units within medical/surgical hospitals owned by others.
-- July 30, 2009 Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) closed at $30.66 on a volume of 322,388 shares
In a press release on july 31, 2009 U.S. Food and Drug Administration's Arthritis Advisory Committee Confirms Date to Review XIAFLEX(TM) for the Treatment of Dupuytren's Contracture
MALVERN, PA, Jul 31, 2009 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee confirmed it will review XIAFLEX(TM) during an advisory committee hearing at the Holiday Inn in Gaithersburg, MD on September 16, 2009. The Arthritis Advisory Committee is an official advisory committee of the FDA's Division of Anesthesia, Analgesia and Rheumatology Products (DAARP). Advisory committees provide the FDA with independent expert advice on scientific, technical, and policy matters.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase Clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's contracture, and the biologics license application is under review at the FDA for the treatment of Dupuytren's contracture. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations. For additional information, visit http://www.auxilium.com.
-- July 30, 2009 Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) closed at $6.79 on a volume of 38,576 shares.
In a press release out on July 30, 2009 Idera Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Jul 31, 2009 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the following conferences:
-- The BMO Capital Markets 9th Annual Focus on Healthcare Conference, on Wednesday, August 5 at 1:15 p.m. EDT at the Millennium Broadway Hotel in New York City.
-- The 29th Annual Canaccord Adams Global Growth Conference, on Wednesday, August 12 at 9:30 a.m. EDT at the Intercontinental Hotel in Boston.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.
-- July 30, 2009 Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) closed at $6.51 on a volume of 27,880 shares.
In a press release out on July 31, 2009 Sucampo to Release Second Quarter 2009 Financial Results and Conduct a Conference Call on August 6, 2009
BETHESDA, Md., Jul 31, 2009 -- Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended June 30, 2009. These results are expected to be released on Thursday, August 6, 2009, after the capital markets close.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development and a member of the Board of Directors.
Sucampo Pharma America, Inc., markets AMITIZA(R) (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and AMITIZA 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
-- July 30, 2009 GTC Biotherapeutics, Inc.'s ("GTC", Nasdaq: GTCB) closed at $2.21 on a volume of 12,446 shares.
In a press release out on July 31, 2009 GTC Biotherapeutics Reports Second Quarter 2009 Financial Results
FRAMINGHAM, Mass., Jul 31, 2009 -- GTC Biotherapeutics, Inc.'s ("GTC", Nasdaq: GTCB) total net loss for the second quarter ended June 28, 2009, was $10.8 million, or $1.03 per share, compared to $2.2 million, or $0.22 per share, for the second quarter of 2008. The total net loss for the first six months of 2009 was $21.1 million, or $2.03 per share, compared to $10.4 million, or $1.12 per share, for the first six months of 2008. The first half of 2008 included significant sales of ATryn(R) to our former partner in Europe, LEO Pharma A/S. While revenues for the first six months of 2009 were approximately $0.9 million, during that same period there were $5.7 million of milestones received that were not recognized as revenue and were recorded as deferred revenue on the balance sheet. Subsequent to yesterday's special shareholder vote, GTC is receiving $8.3 million of additional funding from LFB Biotechnologies upon the first closing under the June 18, 2009 agreement for the sale of new convertible preferred stock.
About GTC Biotherapeutics, Inc.
GTC Biotherapeutics develops, supplies and commercializes therapeutic proteins produced through transgenic animal technology. ATryn(R), GTC's recombinant human antithrombin, has been approved for use in the United States and Europe. ATryn is the first and only product produced in transgenic animals to be approved for therapeutic use anywhere in the world. In addition to ATryn, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa and IX, which are being developed for the treatment of hemophilia. GTC is also developing a portfolio of follow-on biologic monoclonal antibodies and a CD20 antibody with enhanced ADCC (antibody-dependent cell-mediated cytotoxicity). GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
-- July 30, 2009 Medarex, Inc. (NASDAQ:MEDX) closed at $15.91 on a volume of 7,444,775 shares
In a press release out on July 31, 2009 Medarex Announces 2009 Second Quarter Financial Results
PRINCETON, N.J., Jul 31, 2009 -- Medarex, Inc. (NASDAQ:MEDX) announced today its financial results for the three-month period ended June 30, 2009.
SAN DIEGO, Jul 30, 2009 -- On a mission to accelerate IP-Cable and IPTV deployments worldwide, Entropic Communications, Inc. (Nasdaq:ENTR), a leading provider of silicon and software solutions to enable connected home entertainment and Sigma Designs (Nasdaq:SIGM), a leader in digital media processing system-on-a-chip (SoC) solutions for consumer electronics, today announced their cooperative relationship to develop high definition, MoCA compliant Cable TV and IPTV Set-Top-Box (STB) reference designs, powered by Entropic's EN2510 and Sigma Designs' SMP8654. Due to debut in the Fall of 2009, the reference designs will bring highly competitive, full-featured set-top box solutions to OEMs and service providers globally.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently approved for commercial sale, the subject of regulatory applications for marketing authorization or in Phase 3 clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
About PicksThatMove.com
www.picksthatmove.com team of excellence strives to find undervalued, good momentum stock plays. We provide financial and investor relations services for small to mid-cap stocks with weekly and special newsletters to keep you informed of the latest movers. Unlike other sites, we explore, research, and understand all aspects of a company. We only recommend companies we feel has the potential for future higher valuations. Our seasoned research team is always looking for the next Xtreme Pick to send to you.
www.picksthatmove.com is a leading stock website that provides free daily alerts on stocks that are moving up. www.picksthatmove.com also tracks small cap stocks that are on the brink of exploding. We also feature companies on our website with research report, analysis, and newsletters. To feature a company on our web site please contact us at Info@picksthatmove.com
www.picksthatmove.com is an independent electronic publication that provides information on selected publicly traded companies. www.picksthatmove.com is not a registered investment advisor or broker-dealer. www.picksthatmove.com affiliates, officers, directors and employees may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Contact Center Solutions Homepage's Homepage ]
|
NextiraOne Obtains Cisco's Unified Contact Centre Enterprise ATP Status 
BUYINS.NET: SMBL, HBNK, HALO, CYNO, VG, EONC Are Seasonally Ripe To Go Down In the Next Five Weeks
NEW Consolidating Infrastructures: IT's New Call to Business [white paper]
